Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiviral Therapy After Radical Resection for HBV-Related Hepatocellular Carcinoma
NCT00768157Phase 4Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lamivudine and entecavir in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 5 years. Status: unknown.
02
Drugs
lamivudineentecavir
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00768157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00768157.